C3 glomerulonephritis in a patient treated with anti–PD-1 antibody

Simon Ville; Christine Kandel-Aznar; Veronique Fremeaux-Bacchi; Fadi Fakhouri

doi:10.1016/j.ejca.2019.11.011

Journal articles

C3 glomerulonephritis in a patient treated with anti–PD-1 antibody

Simon Ville ^{1, 2} Christine Kandel-Aznar ³ Veronique Fremeaux-Bacchi ^{4, 5} Fadi Fakhouri ^{1, 2}

1 U1064 Inserm - CRTI - Centre de Recherche en Transplantation et Immunologie

2 ITUN - Institut de transplantation urologie-néphrologie

3 CHU Nantes - Centre hospitalier universitaire de Nantes

4 Laboratoire d'Immunologie Biologique

5 CRC (UMR_S_1138 / U1138) - Centre de Recherche des Cordeliers

Abstract : Immune checkpoint inhibitors (ICIs) have dramati-cally transformed the treatment of solid tumors. ICIsinduce an immune response against tumoral cells as aresult of the removal of T-cell inhibition [1]. The logicalcounterpart of turning off T-cell inhibitory mechanismsis the onset of immune-related adverse events (irAEs)that affect different organs. Although the most frequentrenal irAE is acute interstitial nephritis [2], we report afirst case of C3 glomerulonephritis (GN) associated withthe use of an antieProgrammed Cell Death 1 (PD-1)humanised antibody.

Document type :

Journal articles

Domain :

Life Sciences [q-bio]

Complete list of metadatas

https://www.hal.inserm.fr/inserm-02449014
Contributor : Sylvie Le Bihan <>
Submitted on : Wednesday, January 22, 2020 - 4:03:35 PM
Last modification on : Friday, September 18, 2020 - 2:35:04 PM

C3 glomerulonephritis in a patient treated with anti–PD-1 antibody

Identifiers

Collections

Citation

Export

Metrics

367

C3 glomerulonephritis in a patient treated with anti–PD-1 antibody

Identifiers

Collections

Citation

Export

Share

Metrics

367